Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | CASP3 | P42574 | 1/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758756 | 1.00 | GFER (1.00) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL10041971 | 0.82 | CASP3 (0.70) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL29510116 | 0.82 | CASP3 (0.70) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL8485793 | 0.82 | CASP3 (0.70) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL8306489 | 0.82 | CASP3 (0.70) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL28252406 | 0.81 | CASP3 (0.68) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL27831966 | 0.77 | CASP3 (0.63) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL30301801 | 0.77 | ALDH1A1 (0.82) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL9806289 | 0.77 | CASP3 (0.62) | GFERCASP3SENP8SENP7SENP6 | |
| SCHEMBL50671 | 0.77 | ALDH1A1 (0.82) | GFERCASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108822135-A | A kind of synthetic method of the cyclosubstituted thieno of azepine [3,2-d] thiazole and its derivative | 湘潭大学 | 2018-11-16 | — | — | CN | claimed |
| CN-110606855-B | Polysubstituted benzothienoisoquinoline, derivative and synthesis method thereof | 湘潭大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-108822135-A | A kind of synthetic method of the cyclosubstituted thieno of azepine [3,2-d] thiazole and its derivative | 湘潭大学 | 2018-11-16 | — | — | CN | disclosed |
| EP-1828143-B1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2013-03-20 | — | — | EP | disclosed |
| US-7943649-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2011-05-17 | — | — | US | disclosed |
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| US-7442716-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | PTGES, PTGS1, PTGES2 | GFER 2862/4885CASP3 4329/4885SENP8 3803/4885 |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | GSTO1, PTGS1, PTGES | GFER 765/4885CASP3 1658/4885SENP8 2948/4885 |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | GFER 2622/4885CASP3 4310/4885SENP8 3854/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | GFER 2622/4885CASP3 4310/4885SENP8 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.